PNMA1

Across TCGA pan-cancer cohorts, PNMA1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PNMA1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PNMA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PNMA1 expression acts as an unfavorable survival marker.

KIRP, ESCA, and LUAD are the cancer types where PNMA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.088	0.920	<.001	48	view →
ESCA	DFS	Median	All	0.081	0.536	<.001	36	view →
LUAD	OS	Median	All	0.068	0.812	<.001	36	view →
OV	DFS	Median	All	0.171	0.542	.008	18	view →
CESC	OS	Median	All	0.138	0.589	.035	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PNMA1–KIRP (DFS)

Open the KIRP breakdown →